Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 167

1.

Antiglaucoma EP2 Agonists: A Long Road That Led Somewhere.

Woodward DF, Wang JW, Stamer WD, Lütjen-Drecoll E, Krauss AH, Toris CB.

J Ocul Pharmacol Ther. 2019 Nov;35(9):469-474. doi: 10.1089/jop.2019.0041. Epub 2019 Jul 19.

PMID:
31329508
2.

A Highly Effective and Ultra-Long-Acting Anti-Glaucoma Drug, with a Novel Periorbital Delivery Method.

Woodward DF, Wang JW, Coleman RA, Woodrooffe AJ, Clark KL, Stamer WD, Tao G, Fan S, Toris CB.

J Ocul Pharmacol Ther. 2019 Jun;35(5):265-277. doi: 10.1089/jop.2018.0126. Epub 2019 Apr 25.

PMID:
31025909
3.

In Vivo Choroidal Neovascularization and Macrophage Studies Provide Further Evidence for a Broad Role of Prostacyclin in Angiogenesis.

Woodward DF, Wang JW, Ni M, Bauer AJ, Poloso NJ.

J Ocul Pharmacol Ther. 2019 Mar;35(2):98-105. doi: 10.1089/jop.2018.0077. Epub 2018 Dec 14.

PMID:
30547709
4.

The affinity, intrinsic activity and selectivity of a structurally novel EP2 receptor agonist at human prostanoid receptors.

Coleman RA, Woodrooffe AJ, Clark KL, Toris CB, Fan S, Wang JW, Woodward DF.

Br J Pharmacol. 2019 Mar;176(5):687-698. doi: 10.1111/bph.14525. Epub 2019 Jan 4.

5.

FAAH-Catalyzed C-C Bond Cleavage of a New Multitarget Analgesic Drug.

Ligresti A, Silvestri C, Vitale RM, Martos JL, Piscitelli F, Wang JW, Allarà M, Carling RW, Luongo L, Guida F, Illiano A, Amoresano A, Maione S, Amodeo P, Woodward DF, Di Marzo V, Marino G.

ACS Chem Neurosci. 2019 Jan 16;10(1):424-437. doi: 10.1021/acschemneuro.8b00315. Epub 2018 Oct 4.

PMID:
30226747
6.

Differential response and withdrawal profile of glucocorticoid-treated human trabecular meshwork cells.

Li G, Cui G, Dismuke WM, Navarro I, Perkumas K, Woodward DF, Stamer WD.

Exp Eye Res. 2017 Feb;155:38-46. doi: 10.1016/j.exer.2016.12.002. Epub 2016 Dec 7.

7.

In vivo studies validating multitargeting of prostanoid receptors for achieving superior anti-inflammatory effects.

Woodward DF, Wang JW, Ni M, Bauer A, Martos JL, Carling RW, Poloso NJ.

FASEB J. 2017 Jan;31(1):368-375. doi: 10.1096/fj.201600604R. Epub 2016 Oct 21.

PMID:
27770021
8.

Prostanoid Receptor Antagonist Effects on Intraocular Pressure, Supported by Ocular Biodisposition Experiments.

Woodward DF, Wenthur SL, Rudebush TL, Fan S, Toris CB.

J Ocul Pharmacol Ther. 2016 Nov;32(9):606-622. Epub 2016 Oct 20. Erratum in: J Ocul Pharmacol Ther. 2016 Dec;32(10 ):695.

PMID:
27763812
9.

Prostaglandin E2-Glyceryl Ester: In Vivo Evidence for a Distinct Pharmacological Identity from Intraocular Pressure Studies.

Woodward DF, Poloso NJ, Wang JW.

J Pharmacol Exp Ther. 2016 Aug;358(2):173-80. doi: 10.1124/jpet.116.232512. Epub 2016 May 23.

PMID:
27217589
10.

Multitargeting of selected prostanoid receptors provides agents with enhanced anti-inflammatory activity in macrophages.

Wang JW, Woodward DF, Martos JL, Cornell CL, Carling RW, Kingsley PJ, Marnett LJ.

FASEB J. 2016 Jan;30(1):394-404. doi: 10.1096/fj.15-275610. Epub 2015 Sep 29.

PMID:
26420849
11.

Identification of prostamides, fatty acyl ethanolamines, and their biosynthetic precursors in rabbit cornea.

Urquhart P, Wang J, Woodward DF, Nicolaou A.

J Lipid Res. 2015 Aug;56(8):1419-33. doi: 10.1194/jlr.M055772. Epub 2015 May 31.

12.

Endocannabinoids and their oxygenation by cyclo-oxygenases, lipoxygenases and other oxygenases.

Urquhart P, Nicolaou A, Woodward DF.

Biochim Biophys Acta. 2015 Apr;1851(4):366-76. doi: 10.1016/j.bbalip.2014.12.015. Epub 2014 Dec 24. Review.

PMID:
25543004
13.

Ultrastructural changes associated with dexamethasone-induced ocular hypertension in mice.

Overby DR, Bertrand J, Tektas OY, Boussommier-Calleja A, Schicht M, Ethier CR, Woodward DF, Stamer WD, Lütjen-Drecoll E.

Invest Ophthalmol Vis Sci. 2014 Jul 15;55(8):4922-33. doi: 10.1167/iovs.14-14429.

14.

Recent progress in prostaglandin F2α ethanolamide (prostamide F2α) research and therapeutics.

Woodward DF, Wang JW, Poloso NJ.

Pharmacol Rev. 2013 Jul 26;65(4):1135-47. doi: 10.1124/pr.112.007088. Print 2013. Review.

PMID:
23893067
15.

Anandamide-derived prostamide F2α negatively regulates adipogenesis.

Silvestri C, Martella A, Poloso NJ, Piscitelli F, Capasso R, Izzo A, Woodward DF, Di Marzo V.

J Biol Chem. 2013 Aug 9;288(32):23307-21. doi: 10.1074/jbc.M113.489906. Epub 2013 Jun 25.

16.

Differential effects of prostaglandin E2-sensitive receptors on contractility of human ocular cells that regulate conventional outflow.

Wang JW, Woodward DF, Stamer WD.

Invest Ophthalmol Vis Sci. 2013 Jul 16;54(7):4782-90. doi: 10.1167/iovs.13-12363.

17.

Nature of the slow relaxation of smooth muscle induced by a EP2 receptor agonist with a non-prostanoid structure.

Jones RL, Wan Ahmad WA, Woodward DF, Wang J.

Prostaglandins Leukot Essent Fatty Acids. 2013 Apr;88(4):321-30. doi: 10.1016/j.plefa.2013.01.007. Epub 2013 Feb 16.

PMID:
23419768
18.

PGE2 differentially regulates monocyte-derived dendritic cell cytokine responses depending on receptor usage (EP2/EP4).

Poloso NJ, Urquhart P, Nicolaou A, Wang J, Woodward DF.

Mol Immunol. 2013 Jul;54(3-4):284-95. doi: 10.1016/j.molimm.2012.12.010. Epub 2013 Jan 20.

PMID:
23337716
19.

The biodisposition and hypertrichotic effects of bimatoprost in mouse skin.

Woodward DF, Tang ES, Attar M, Wang JW.

Exp Dermatol. 2013 Feb;22(2):145-8. doi: 10.1111/exd.12071. Epub 2013 Jan 2.

20.

The prostamide-related glaucoma therapy, bimatoprost, offers a novel approach for treating scalp alopecias.

Khidhir KG, Woodward DF, Farjo NP, Farjo BK, Tang ES, Wang JW, Picksley SM, Randall VA.

FASEB J. 2013 Feb;27(2):557-67. doi: 10.1096/fj.12-218156. Epub 2012 Oct 26.

21.

Pharmacologic manipulation of conventional outflow facility in ex vivo mouse eyes.

Boussommier-Calleja A, Bertrand J, Woodward DF, Ethier CR, Stamer WD, Overby DR.

Invest Ophthalmol Vis Sci. 2012 Aug 24;53(9):5838-45. doi: 10.1167/iovs.12-9923.

22.

Immunohistochemical demonstration of increased prostaglandin F₂α levels in the rat hippocampus following kainic acid-induced seizures.

Takei S, Hasegawa-Ishii S, Uekawa A, Chiba Y, Umegaki H, Hosokawa M, Woodward DF, Watanabe K, Shimada A.

Neuroscience. 2012 Aug 30;218:295-304. doi: 10.1016/j.neuroscience.2012.05.013. Epub 2012 May 17.

PMID:
22609937
23.

Prostanoid EP₁ receptors mediate up-regulation of the orphan nuclear receptor Nurr1 by cAMP-independent activation of protein kinase A, CREB and NF-κB.

Ji R, Sanchez CM, Chou CL, Chen XB, Woodward DF, Regan JW.

Br J Pharmacol. 2012 Jun;166(3):1033-46. doi: 10.1111/j.1476-5381.2011.01817.x. Erratum in: Br J Pharmacol. 2017 Jul;174(13):2156.

24.

International Union of Basic and Clinical Pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress.

Woodward DF, Jones RL, Narumiya S.

Pharmacol Rev. 2011 Sep;63(3):471-538. doi: 10.1124/pr.110.003517. Epub 2011 Jul 13. Review.

PMID:
21752876
25.

The role of the prostaglandin EP4 receptor in the regulation of human outflow facility.

Millard LH, Woodward DF, Stamer WD.

Invest Ophthalmol Vis Sci. 2011 Jun 1;52(6):3506-13. doi: 10.1167/iovs.10-6510.

PMID:
21245402
26.

Roles of affinity and lipophilicity in the slow kinetics of prostanoid receptor antagonists on isolated smooth muscle preparations.

Jones RL, Woodward DF, Wang JW, Clark RL.

Br J Pharmacol. 2011 Feb;162(4):863-79. doi: 10.1111/j.1476-5381.2010.01087.x.

27.

Interaction of prostanoid EP₃ and TP receptors in guinea-pig isolated aorta: contractile self-synergism of 11-deoxy-16,16-dimethyl PGE₂.

Jones RL, Woodward DF.

Br J Pharmacol. 2011 Jan;162(2):521-31. doi: 10.1111/j.1476-5381.2010.01039.x.

28.

Preferential localization of prostamide/prostaglandin F synthase in myelin sheaths of the central nervous system.

Yoshikawa K, Takei S, Hasegawa-Ishii S, Chiba Y, Furukawa A, Kawamura N, Hosokawa M, Woodward DF, Watanabe K, Shimada A.

Brain Res. 2011 Jan 7;1367:22-32. doi: 10.1016/j.brainres.2010.10.019. Epub 2010 Oct 13.

PMID:
20950588
29.

Bimatoprost effects on aqueous humor dynamics in monkeys.

Woodward DF, Krauss AH, Nilsson SF.

J Ophthalmol. 2010;2010:926192. doi: 10.1155/2010/926192. Epub 2010 May 23.

30.

Induction of angiogenic immediate early genes by activation of FP prostanoid receptors in cultured human ciliary smooth muscle cells.

Hutchinson AJ, Coons SC, Chou CL, Xu W, Stamer WD, Woodward DF, Regan JW.

Curr Eye Res. 2010 May;35(5):408-18. doi: 10.3109/02713680903581021.

PMID:
20450254
31.

Cellular basis for bimatoprost effects on human conventional outflow.

Stamer WD, Piwnica D, Jolas T, Carling RW, Cornell CL, Fliri H, Martos J, Pettit SN, Wang JW, Woodward DF.

Invest Ophthalmol Vis Sci. 2010 Oct;51(10):5176-81. doi: 10.1167/iovs.09-4955. Epub 2010 Apr 30.

32.

Characterization of an in vivo model for the study of eyelash biology and trichomegaly: mouse eyelash morphology, development, growth cycle, and anagen prolongation by bimatoprost.

Tauchi M, Fuchs TA, Kellenberger AJ, Woodward DF, Paus R, Lütjen-Drecoll E.

Br J Dermatol. 2010 Jun;162(6):1186-97. doi: 10.1111/j.1365-2133.2010.09685.x. Epub 2010 Mar 12.

PMID:
20346040
33.

EP1 prostanoid receptor coupling to G i/o up-regulates the expression of hypoxia-inducible factor-1 alpha through activation of a phosphoinositide-3 kinase signaling pathway.

Ji R, Chou CL, Xu W, Chen XB, Woodward DF, Regan JW.

Mol Pharmacol. 2010 Jun;77(6):1025-36. doi: 10.1124/mol.110.063933. Epub 2010 Mar 24.

34.

Structural determinants for calcium mobilization by prostaglandin E2 and prostaglandin F2alpha glyceryl esters in RAW 264.7 cells and H1819 cells.

Richie-Jannetta R, Nirodi CS, Crews BC, Woodward DF, Wang JW, Duff PT, Marnett LJ.

Prostaglandins Other Lipid Mediat. 2010 Jun;92(1-4):19-24. doi: 10.1016/j.prostaglandins.2010.01.003. Epub 2010 Feb 10.

35.

Lipidomic analysis reveals prostanoid profiles in human term pregnant myometrium.

Durn JH, Marshall KM, Farrar D, O'Donovan P, Scally AJ, Woodward DF, Nicolaou A.

Prostaglandins Leukot Essent Fatty Acids. 2010 Jan;82(1):21-6. doi: 10.1016/j.plefa.2009.11.002. Epub 2009 Dec 1.

PMID:
19954938
36.

Synthesis and biological evaluation of piperazinyl carbamates and ureas as fatty acid amide hydrolase (FAAH) and transient receptor potential (TRP) channel dual ligands.

Morera E, De Petrocellis L, Morera L, Moriello AS, Ligresti A, Nalli M, Woodward DF, Di Marzo V, Ortar G.

Bioorg Med Chem Lett. 2009 Dec 1;19(23):6806-9. doi: 10.1016/j.bmcl.2009.09.033. Epub 2009 Oct 20.

PMID:
19875281
37.

Prostanoid receptor antagonists: development strategies and therapeutic applications.

Jones RL, Giembycz MA, Woodward DF.

Br J Pharmacol. 2009 Sep;158(1):104-45. doi: 10.1111/j.1476-5381.2009.00317.x. Epub 2009 Jul 15. Review.

38.

Prostanoid EP4 receptor stimulation produces ocular hypotension by a mechanism that does not appear to involve uveoscleral outflow.

Woodward DF, Nilsson SF, Toris CB, Kharlamb AB, Nieves AL, Krauss AH.

Invest Ophthalmol Vis Sci. 2009 Jul;50(7):3320-8. doi: 10.1167/iovs.08-3031. Epub 2009 Feb 21.

PMID:
19234340
39.

The pharmacology and therapeutic relevance of endocannabinoid derived cyclo-oxygenase (COX)-2 products.

Woodward DF, Carling RW, Cornell CL, Fliri HG, Martos JL, Pettit SN, Liang Y, Wang JW.

Pharmacol Ther. 2008 Oct;120(1):71-80. doi: 10.1016/j.pharmthera.2008.08.001. Epub 2008 Aug 6. Review.

PMID:
18700152
40.

Identification and pharmacological characterization of the prostaglandin FP receptor and FP receptor variant complexes.

Liang Y, Woodward DF, Guzman VM, Li C, Scott DF, Wang JW, Wheeler LA, Garst ME, Landsverk K, Sachs G, Krauss AH, Cornell C, Martos J, Pettit S, Fliri H.

Br J Pharmacol. 2008 Jul;154(5):1079-93. doi: 10.1038/bjp.2008.142. Epub 2008 Apr 21.

41.

Loss of prostaglandin F2alpha, but not thromboxane, responsiveness in pregnant human myometrium during labour.

Fischer DP, Hutchinson JA, Farrar D, O'Donovan PJ, Woodward DF, Marshall KM.

J Endocrinol. 2008 Apr;197(1):171-9. doi: 10.1677/JOE-07-0494.

PMID:
18372243
42.

Endogenous Bioactive Lipids and the Regulation of Conventional Outflow Facility.

Wan Z, Woodward DF, Stamer WD.

Expert Rev Ophthalmol. 2008;3(4):457-470.

43.

New N-arachidonoylserotonin analogues with potential "dual" mechanism of action against pain.

Ortar G, Cascio MG, De Petrocellis L, Morera E, Rossi F, Schiano-Moriello A, Nalli M, de Novellis V, Woodward DF, Maione S, Di Marzo V.

J Med Chem. 2007 Dec 27;50(26):6554-69. Epub 2007 Nov 21.

PMID:
18027904
44.

Molecular characterization of a novel type of prostamide/prostaglandin F synthase, belonging to the thioredoxin-like superfamily.

Moriuchi H, Koda N, Okuda-Ashitaka E, Daiyasu H, Ogasawara K, Toh H, Ito S, Woodward DF, Watanabe K.

J Biol Chem. 2008 Jan 11;283(2):792-801. Epub 2007 Nov 15.

45.

Bimatoprost, prostamide activity, and conventional drainage.

Wan Z, Woodward DF, Cornell CL, Fliri HG, Martos JL, Pettit SN, Wang JW, Kharlamb AB, Wheeler LA, Garst ME, Landsverk KJ, Struble CS, Stamer WD.

Invest Ophthalmol Vis Sci. 2007 Sep;48(9):4107-15.

46.

Prostamides (prostaglandin-ethanolamides) and their pharmacology.

Woodward DF, Liang Y, Krauss AH.

Br J Pharmacol. 2008 Feb;153(3):410-9. Epub 2007 Aug 27. Review.

47.

A historical perspective and recent advances in prostamide research and therapeutics.

Burk RM, Woodward DF.

Curr Opin Drug Discov Devel. 2007 Jul;10(4):413-21. Review.

PMID:
17659482
48.

Fixed-combination and emerging glaucoma therapies.

Woodward DF, Chen J.

Expert Opin Emerg Drugs. 2007 May;12(2):313-27. Review.

PMID:
17604504
49.

Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors.

Maione S, De Petrocellis L, de Novellis V, Moriello AS, Petrosino S, Palazzo E, Rossi FS, Woodward DF, Di Marzo V.

Br J Pharmacol. 2007 Mar;150(6):766-81. Epub 2007 Feb 5.

50.

Identification of an antagonist that selectively blocks the activity of prostamides (prostaglandin-ethanolamides) in the feline iris.

Woodward DF, Krauss AH, Wang JW, Protzman CE, Nieves AL, Liang Y, Donde Y, Burk RM, Landsverk K, Struble C.

Br J Pharmacol. 2007 Feb;150(3):342-52. Epub 2006 Dec 18.

Supplemental Content

Loading ...
Support Center